SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C.  20549

                                  FORM 10-QSB

                       FOR QUARTER ENDED MARCH 31, 1999

                QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D)
                  OF THE SECURITIES AND EXCHANGE ACT OF 1934

                        COMMISSION FILE NUMBER 1-10768
                                               -------


                      MEDIWARE INFORMATION SYSTEMS, INC.
            (Exact name of registrant as specified in its charter)

            New York                                   11-2209324
     (State of other Jurisdiction of                (I.R.S. Employer
      incorporation or organization)             Identification Number)


     1121 Old Walt Whitman Road
     Melville, New York                                  11747-3005
    (Address of Principal Executive Officer)            (Zip  Code)


                                (516) 423-7800
             (Registrant's telephone number, including area code)


Indicate  by  check  mark  whether  the  registrant  (1) has filed all reports
required  to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934  during  the  preceding  12  months  (or for such shorter period that the
registrant was required to file such reports) and (2) has been subject to such
filing  requirements  for  the  past  90  Days.     Yes      X       No ______
                                                          ------

As  of  March 31, 1999, there were 6,096,000 shares of Common Stock, $0.10 par
value,  of  the  registrant  outstanding.




<PAGE>

<TABLE>
<CAPTION>

                 MEDIWARE  INFORMATION  SYSTEMS,  INC.

                                 INDEX

Part I.    Financial Information                                   Page
                                                                   ----
<S>        <C>                                                     <C>
                                                          <C>          <C>

ITEM 1.    Financial Statements
           Consolidated Balance Sheets as of March 31, 1999
           (unaudited) and June 30, 1998 (audited)                  2

           Consolidated Statements of Operations
           for the three months and nine months ended
           March 31, 1999 & 1998 (unaudited)                        3

           Consolidated Statements of Cash Flows
           for the nine months ended
           March 31, 1999 & 1998 (unaudited)                        4

           Notes to Financial Statements                            5

ITEM 2.    Management's Discussion and Analysis of Financial
           Condition and Results of Operations                      6

           Year 2000 Compliance                                     9

Signature Page                                                     14

Exhibit 11
Schedule of Computation of Net Income per Share                    15

Exhibit 27
Financial Data Schedule                                            16

</TABLE>


<PAGE>

<TABLE>
<CAPTION>

                         MEDIWARE INFORMATION SYSTEMS, INC. AND SUBSIDIARIES
                                   CONSOLIDATED BALANCE SHEETS
<S>                                                                     <C>           <C>
                                                                                <C>           <C> 
                           ASSETS                                           Mar-31        Jun-30
                          --------                                           1999          1998 
                                                                         (unaudited)
                                                                        ------------   -----------
Current assets:
   Cash and cash equivalents                                            $ 3,658,000   $ 4,681,000 
   Accounts receivable, less allowance for doubtful accounts
       of $472,000 at March 31, 1999 and $490,000 at June 30, 1998        8,863,000     7,485,000 
   Inventories                                                              453,000       331,000 
   Deferred Tax Asset                                                       550,000       550,000 
   Prepaid expenses and other current assets                                712,000       514,000 
                                                                        ------------  ------------
        Total current assets                                             14,236,000    13,561,000 

   Fixed assets, at cost, less accumulated depreciation of $2,431,000
      at March 31, 1999 and $2,058,000 at June 30, 1998                   1,819,000     1,170,000 
   Capitalized software costs                                             3,262,000     2,444,000 
   Excess of cost over fair value of net assets acquired, net of
      accumulated amortization of $1,384,000 at March 31, 1999
      and $1,091,000 at June 30, 1998                                     6,458,000     5,853,000 
   Purchased technology less accumulated amortization of $35,000 at
      March 31, 1999                                                        463,000 
   Other assets                                                             237,000       719,000 
                                                                        ------------  ------------
                                                                        $26,475,000   $23,747,000 
                                                                        ============  ============

                        LIABILITIES
                       -------------
Current liabilities:
   Accounts payable                                                     $ 1,344,000   $ 1,176,000 
   Notes payable                                                            854,000     4,600,000 
   Accrued expenses and other current liabilities                         2,926,000     2,618,000 
   Advances from customers                                                5,916,000     3,132,000 
   Current portion of capital leases payable                                 11,000         9,000 
                                                                        ------------  ------------
        Total current liabilities                                        11,051,000    11,535,000 
   Advances from customers - long term                                       10,000         7,000 
   Other liabilities - long term                                            106,000               
   Capital leases payable, less current portion                              10,000        15,000 
                                                                        ------------  ------------
        Total liabilities                                                11,177,000    11,557,000 
                                                                        ------------  ------------

                    STOCKHOLDERS' EQUITY
                   -----------------------
Preferred stock - $.01 par value; authorized 10,000,000 shares;
    none issued and outstanding
Common stock - $.10 par value;  authorized 12,000,000 shares;
    issued and outstanding; 6,096,000 shares at March 31, 1999
    and 5,591,000 shares at June 30, 1998                                   610,000       559,000 
Unearned compensation                                                       (21,000)      (51,000)
Cumulative foreign currency translation adjustment                           20,000        36,000 
Additional paid-in capital                                               21,164,000    16,264,000 
(Deficit)                                                                (6,475,000)   (4,618,000)
                                                                        ------------  ------------
        Total stockholders' equity                                       15,298,000    12,190,000 
                                                                        ------------  ------------
                                                                        $26,475,000   $23,747,000 
                                                                        ============  ============
</TABLE>

<PAGE>

<TABLE>
<CAPTION>

                   MEDIWARE INFORMATION SYSTEMS, INC. AND SUBSIDIARIES
                        CONSOLIDATED STATEMENTS OF OPERATIONS
                                    (UNAUDITED)

                                      Three Months Ended March  31,  Nine Months Ended March  31,
                                      -----------------------------  ---------------------------
                                                (unaudited)                     (unaudited)
                                             1999           1998         1999           1998
                                      ----------------------------  ----------------------------
<S>                                    <C>              <C>          <C>            <C>
                                                    <C>          <C>            <C>           <C> 
REVENUES:
    System sales                          $ 3,284,000   $1,985,000   $  9,246,000   $ 5,046,000 
    Services                                4,015,000    3,197,000     11,117,000     9,503,000 
                                       ---------------  -----------  -------------  ------------

      Total revenues                        7,299,000    5,182,000     20,363,000    14,549,000 
                                       ---------------  -----------  -------------  ------------
COSTS AND EXPENSES:
  Cost of systems                           1,080,000      670,000      2,897,000     1,701,000 
  Cost of services                          1,031,000      828,000      3,023,000     2,306,000 
  Purchased research and development                                    4,553,000               
  Software development costs                  859,000      716,000      2,380,000     1,898,000 
    Selling, general and administrative     3,174,000    2,188,000      8,837,000     6,193,000 
                                       ---------------  -----------  -------------  ------------
     Total Costs & Expenses                 6,144,000    4,402,000     21,690,000    12,098,000 

Earnings (Loss) before interest and taxes   1,155,000      780,000     (1,327,000)    2,451,000 
Interest and other income                      20,000       56,000         90,000       161,000 
Interest (expense)                            (37,000)    (152,000)      (143,000)     (426,000)
                                       ---------------  -----------  -------------  ------------
Earnings (Loss) before taxes                1,138,000      684,000     (1,380,000)    2,186,000 
Provision for income taxes                    172,000       35,000        477,000       121,000 
                                       ---------------  -----------  -------------  ------------

NET EARNINGS (LOSS)                    $      966,000   $  649,000    ($1,857,000)  $ 2,065,000 
                                       ===============  ===========  =============  ============
Basic earnings (loss) per share                 $ .16        $ .12          ($.31)        $ .38 
Diluted earnings (loss) per share               $ .14        $ .10          ($.31)        $ .31 

Weighted average shares outstanding         6,066,000    5,523,000      5,914,000     5,417,000 
                                       ===============  ===========  =============  ============
Average shares outstanding assuming
Dilution                                    7,095,000    6,708,000      5,914,000     6,565,000 
                                       ===============  ===========  =============  ============


<PAGE>



</TABLE>
<TABLE>
<CAPTION>


                    MEDIWARE INFORMATION SYSTEMS, INC. AND SUBSIDIARIES
                         CONSOLIDATED STATEMENTS OF CASH FLOWS
                                     (UNAUDITED)

                                                                        Nine Months Ended
                                                                 ------------------------------
<S>                                                           <C>                  <C>
                                                                             <C>           <C> 
                                                                      March 31         March 31
                                                                        1999              1998 
                                                                   --------------  ------------

CASH FLOWS FROM OPERATING ACTIVITIES:
   Net earnings                                                      ($1,857,000)  $ 2,065,000 
   Adjustments to reconcile net earnings  (loss) to net
      cash provided by operating activities: (excluding
      Informedics acquisition)
      Purchased research and development                               4,553,000 
     Shares issued to directors                                           50,000 
     Compensatory stock options issued to consultants                     30,000        30,000 
     Provision for doubtful accounts                                      15,000       128,000 
     Depreciation and amortization                                     1,339,000     1,088,000 
     Changes in operating assets and liabilities
            Accounts receivable                                       (1,067,000)   (1,529,000)
            Inventory                                                   (107,000)     (136,000)
            Prepaid and other assets                                    (431,000)     (801,000)
            Accounts payable, accrued expenses and
            customer advances                                          1,769,000     1,837,000 
                                                                   --------------  ------------
                  Net cash provided by operating activities            4,294,000     2,682,000 
                                                                   --------------  ------------

CASH FLOWS FROM INVESTING ACTIVITIES:
   Acquisitions of fixed assets                                         (969,000)     (639,000)
   Cash received from acquisition of Informedics                         653,000 
   Capitalized software costs                                         (1,437,000)     (957,000)
                                                                   --------------  ------------
          Net cash (used in) investing activities                     (1,753,000)   (1,596,000)
                                                                   --------------  ------------

CASH FLOWS FROM FINANCING ACTIVITIES:
   Proceeds from exercise of options and warrants                        201,000        47,000 
   Proceeds of private placement                                                     2,201,000 
   Repayment of debt                                                  (3,749,000)   (1,199,000)
          Net cash (used in) provided by financing                 --------------  ------------
          Activities                                                  (3,548,000)    1,049,000 
                                                                   --------------  ------------

Effect of exchange rate changes on cash                                  (16,000)       (9,000)

NET INCREASE/ (DECREASE) IN CASH AND                                  (1,023,000)    2,126,000 
  CASH EQUIVALENTS
Cash and cash equivalents, beginning of period                         4,681,000     1,935,000 
                                                                   --------------  ------------

CASH AND CASH EQUIVALENTS, END OF PERIOD                           $   3,658,000   $ 4,061,000 
                                                                   ==============  ============

Supplemental disclosures of cash flow information:
    Cash paid during the period for:
    Interest                                                       $     106,000   $   365,000 

</TABLE>


<PAGE>
              MEDIWARE INFORMATION SYSTEMS, INC., & SUBSIDIARIES
                    NOTES TO UNAUDITED FINANCIAL STATEMENTS

1.     FINANCIAL    STATEMENTS:
       ------------------------

     In  the opinion of management, the accompanying  unaudited, consolidated,
condensed  financial  statements  contain all adjustments necessary to present
fairly the financial position of the Company and its results of operations and
cash  flows for the interim periods presented.  Such financial statements have
been condensed in accordance with the applicable regulations of the Securities
and  Exchange Commission ("SEC") and therefore, do not include all disclosures
required  by  generally  accepted  accounting  principles.     These financial
statements  should be read in conjunction with the Company's audited financial
statements  for  the year ended June 30, 1998 included in the Company's annual
report  filed  on  Form  10-KSB.

     The  results  of operations for the three and nine months ended March 31,
1999  are  not  necessarily  indicative  of the results to be expected for the
entire  fiscal  year.


2.     EARNINGS  (LOSS)  PER  SHARE:
       -----------------------------

     Basic  earnings  per  share have been computed using the weighted average
number  of  shares of common stock of the Company ("Common Stock") outstanding
for  each  period  presented.    In fiscal 1998 and for the three months ended
March  31,  1999,  the dilutive effect of stock options and other common stock
equivalents is included in the calculation of diluted earnings per share using
the  treasury  stock method.  For the nine months ended March 31, 1999, common
stock equivalents are not included in the calculation of loss per share as the
effect  would  be  anti-dilutive.

3.     ACQUISITION:
       ------------

     In  September  1998,  the  Company  acquired  Informedics,  Inc.
("Informedics")  in  exchange for 439,525 shares of the Company's common stock
on  the basis of 1 Company share for each 6.3 Informedics shares.  Informedics
is  developing  a  Web-enabled  software  system technology and also develops,
markets  and  supports  a  line  of  stand-alone  computer-based  management
information  systems  for  use  in  the blood bank and clinical departments of
hospitals.    The  cost  of  the  acquisition,  which  was  accounted for as a
purchase,  aggregated  $7,100,000,  including  acquisition  costs of $801,000,
assumed  liabilities  of  $1,599,000 and $4,700,000 of common stock issued and
options  assumed  (based  on the market price of the Company's common stock in
December  1997,  when  the  acquisition  agreement  was entered into).  Assets
acquired  aggregated  $2,547,000  including  $917,000 of goodwill, $498,000 of
technology  and  $653,000  of  cash.  

<PAGE>

The  following  unaudited  pro forma financial information gives effect to the
merger  as  if it had occurred at the beginning of fiscal years 1998 and 1999.
A  one-time  acquisition  related charge of $4,553,000 for in-process research
and  development  which  was  recorded  by  the Company on consummation of the
acquisition  and  the  fiscal  1998  reversal of net tax assets on Informedics
financial  statements  has  not been considered in the pro forma results.  The
pro  forma  financial  information does not necessarily reflect the results of
operations  that  would  have  occurred had the acquisition taken place during
such  periods.

<TABLE>
<CAPTION>

                                Nine Months Ended March 31,
                               -----------------------------
                                    1999             1998
                               -------------     -----------
<S>                            <C>              <C>
                                          <C>             <C>
Revenue:                        $ 20,982,000     $16,814,000
                                ============     ===========
Net earnings                    $  2,667,000     $ 2,287,000
                                ============     ===========
Basic earnings per share                 .44             .39
Diluted earnings per share               .38             .33
</TABLE>

4.     RECENT ACCOUNTING PRONOUNCEMENTS:
       ---------------------------------

     In  October  1997, the American Institute of Certified Public Accountants
issued  Statement of Position 97-2, "Software Revenue Recognition" (SOP 97-2).
SOP  97-2 is effective for transactions entered into in fiscal years beginning
after  December  15,  1997.   Retroactive application of the provisions of SOP
97-2  is  prohibited.

     Accordingly  the Company has adopted SOP 97-2 in its financial statements
in  the  fiscal  year  ended  June  1999.   Such adoption had no effect on the
Company's  results  of  operations.

ITEM 2.     MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
            AND  RESULTS  OF  OPERATIONS.

FORWARD-LOOKING  STATEMENTS:

     Certain  statements  made  in  or  incorporating  this  10-QSB  are
forward-looking  statements,  such as descriptions of Mediware's intentions to
market  new  products,  extend  existing  products,  acquire  or  develop  new
products,  and  utilize  new  channels  of distribution.  Such forward-looking
statements  are  not guarantees of future performance and are subject to risks
and  uncertainties  that  could cause actual results to differ materially from
those expressed or implied in the forward-looking statements.  These risks and
uncertainties  include:   (i) Mediware's past operating results, (ii) the wide
variability  of Mediware's operating results, (iii) the market's acceptance of
the  Company's  WORx  product,  (iv)  the  intense competition in the hospital
computer  software  industry  (v)  the  rapid  and  significant  technological
advances  in the computer software industry, which renders the obsolescence of
computer  programs,  including  the  Company's  within  a short time, (vi) the
effect  of  governmental  regulation  on  the  Company,  (vii)  the  Company's
dependence  upon its key employees, (viii) the Company's ability to manage its
rapid  growth  and  (ix) the risks associated with the Company's international
operations.    Amplification  of  such risks may be found in the "Management's
Discussion  and  Analysis  of  Financial  Condition and Results of Operations"
section  herein  and  in  the  "Risk Factors" section of Mediware's Prospectus
contained  in  the  Registration  Statement  on  Form S-4, File No. 333-57693,
especially  those  under  the  headings  "Need  for  Additional  Financing",
"Variability  of  Operating Results", "Market Acceptance of new WORx Product",
"Competition",  "Technological  Obsolescence;  Continual  Need  for Successful
Marketing  and  Acceptance of New Products", "Product Protection", "Dependence
Upon  Key  Employees",  "Management  of  Growth",  "Risks  Associated  with
International  Operations",  and  "Government  Regulation".  Mediware does not
intend  to  update  publicly  any  forward-looking  statements.

RESULTS  OF  OPERATIONS:

     During  the  first  quarter  the  Company  acquired  Informedics,  Inc.
("Informedics").    Informedics  develops,  markets  and  supports  a  line of
stand-alone computer-based management information systems for use in the blood
bank  and  clinical  departments  of hospitals.  Additionally, Informedics has
been  developing a Web-enabled software system technology called IntraMed.net.
This internet/intranet oriented software is intended to provide the ability to
extract  data  from installed legacy computer systems and then store, download
or manipulate the data.  While no assurances can be made, the Company believes
that Informedics' Web-enabling technology, when implemented and sold to future
and  existing  customers,  will  expand  the  reach  of  the  three  clinical
departments  (Blood  Bank,  Pharmacy  and  Surgical  Suite) Mediware currently
addresses.  The acquisition was completed in September 1998, and was accounted
for  as  a purchase.  The Company's operating results include Informedics from
the  date  of  acquisition,  which  consisted  of  revenues  of $1,449,000 and
operating  expenses  of  $1,380,000.

     Total  Company  revenues  increased  by  40.9% or $2,117,000 and 40.0% or
$5,814,000  for the three and nine months ended March 31, 1999 respectively as
compared  to the  same periods in fiscal 1998.  This increase was reflected in
all  product  lines,  but  was  significantly  related to revenue gains in the
Company's  Pharmacy  Division  and the effects of the Informedics acquisition.

     System sales increased by 65.4% or $1,299,000 and 83.2% or $4,200,000 for
the three and nine months ended March 31, 1999 respectively as compared to the
same periods in fiscal 1998.   For both periods, the increase is primarily due
to  increased system sales in the Company's Pharmacy and Blood Bank Divisions.

     Service  revenues  increased by 25.6% or $818,000 and 17.0% or $1,614,000
for the three and nine months ended March 31, 1999 respectively as compared to
the same periods in fiscal 1998.  The increase is due to the increased service
revenues  in  the  Company's  Pharmacy  division  and  the  acquisition  of
Informedics.    The  March  quarter represented the second full quarter of the
acquisition's  contribution  to  the  Company's'  Blood  Bank  Division.

     Cost  of  systems  includes the cost of computer hardware and sublicensed
software  purchased  from  computer  and software manufacturers by Mediware as
part  of  its  complete  system  offering.  These costs can vary as the mix of
revenue  varies  between  high  margin  proprietary  software and lower margin
computer  hardware  and  sublicensed software components. Cost of systems were
32.9%  of related system sales in the third quarter of fiscal 1999 as compared
to  33.8% of related system sales for the same period in fiscal 1998.  For the
first  nine  months  of the current fiscal year, cost of systems were 31.3% of
related  system  sales  in comparison to 33.7% for the same time period in the
previous  fiscal  year.    Cost of systems increased by 61.2% or $410,000 from
$670,000  in the third quarter of fiscal 1998 to $1,080,000 in the same period
in fiscal 1999.  For the first nine months, cost of systems increased by 70.3%
or  $1,196,000  from  $1,701,000  in fiscal 1998 to $2,897,000 in fiscal 1999.
This  increase  in  cost  is  principally  due to the sharp increase in system
sales.

     Cost  of  services  includes the salaries of client service personnel and
communications  expenses  along with the direct expenses.  Technical employees
can  perform  both  client  services  and  software  development  depending on
customer  requirements.    Thus  the  costs  associated  with  these technical
employees  and  the resulting costs of service which are booked will vary from
period  to period with customers needs. Cost of services increased by $203,000
from  $828,000  in the third quarter of the previous fiscal year to $1,031,000
and  by  $717,000  from $2,306,000 for the first nine months of fiscal 1998 to
$3,023,000  in  the  current  fiscal  year.     Cost of services were 25.7% of
related revenue for the three months ended March 31, 1999 vs. 25.9% of related
revenue  for  the  same  period a year earlier. Year-to-date, cost of services
were  27.2%  of  related revenue vs. 24.3% for the same period in fiscal 1998.
This  increase  in  cost  primarily  reflects  an  increase in technical field
installation and customer support activities related to the Company's Pharmacy
division.

     Software  development  costs include salaries, consulting, documentation,
office  and  other  expenses  incurred  in  product  development  along  with
amortization  of software development cost.  In the first quarter, the Company
recorded  a  one-time  acquisition related charge of $4,553,000 for in-process
research  and  development  by Informedics, Inc. and relating to the estimated
fair  value  of  the  IntraMed.net  technology.   Software  development  costs
increased  $143,000 or 20.0% from $716,000 in the third quarter of fiscal 1998
to  $859,000  in  the  same  period  in fiscal 1999 and $482,000 or 25.4% from
$1,898,000  to  $2,380,000  for  the  first nine months of each fiscal period.
Expenditures    (amounts  including  both  capitalized  and  non-capitalized
expenditures  and  excluding  capitalized  software amortization) for software
development  for  the  three  months  ended  March  1999  were  approximately
$1,154,000  as compared to $985,000 for same time period ended March 1998.  On
a  fiscal  year  to  date  basis,  expenditures  for software development were
$3,197,000  for the first nine months of fiscal 1999 as compared to $2,461,000
for  the  same  time  period  in  fiscal  1998.    Spending on development has
increased  among  all  company  divisions  but  is  principally focused on the
Company's  Pharmacy  Division's  WORx  product  line.   The Company expects to
increase  this  level  of  development  spending as it expands its development
efforts  to  the  Blood  Bank  and Operating Room divisions and integrates the
Web-based  communications  technology.

     Selling,  general and administrative expenses include marketing and sales
salaries,  commissions, travel and advertising expenses.  Also included is bad
debt  expense;  legal,  accounting  and  professional fees; salaries and bonus
expense  for  corporate,  divisional,  financial  and  administrative  staff;
utilities,  rent,  communication  and other office expenses; and other related
direct  administrative expenses.  Selling, general and administrative expenses
increased by  $986,000 or 45.1% from $2,188,000 in the third quarter of fiscal
1998  to  $3,174,000  in  the  same  period  in  fiscal  1999 and increased by
$2,644,000  or 42.7% from $6,193,000 to $8,837,000 in the first nine months of
fiscal  1999.   This increase in cost is due to higher communications, travel,
administrative,  marketing,  legal  and  professional  costs.    This increase
reflects  the  cost  of  managing and growing the Company.   Additionally, the
increase  reflects  the  higher  commission  costs  related to increased sales
volume.

     Net interest expense decreased  $115,000 or 75.7% in the third quarter of
fiscal  1999 vs. the same period a year ago and decreased $283,000 or 66.4% in
the  first  nine months of fiscal 1999 vs. the same period a year ago.  During
the  second  quarter  of  fiscal  1999,  the  Company paid off the outstanding
balance  remaining  from the acquisition of the Pharmakon and JAC divisions of
Continental Healthcare Systems, Inc.  The total principal and interest paid in
the  first  nine  months  of  fiscal  year  1999  was  $3,850,000  compared to
$1,199,000  in  the  previous  year.

     Net earnings for the quarter increased $317,000 or 49.8% from $649,000 to
$966,000  in  the  third quarter of fiscal 1999.  On a year-to-date basis, net
earnings  continue  to  be  directly  affected  by  the  $4,553,000  one-time
acquisition  related charge taken in the first quarter for in-process research
and  development  resulting  in  a net loss of $1,857,000.  Excluding this one
time  charge,  net  earnings  for  the  first nine months ended March 31, 1999
increased  by  30.6%  or $631,000 from $2,065,000 for the first nine months of
fiscal  1998  to  $2,696,000  for  the  same  period  in  fiscal  1999.

LIQUIDITY AND CAPITAL RESOURCES:

     The  Company's  cash  and  cash equivalent position at March 31, 1999 was
$3,658,000,  a  decrease  of $1,023,000 from June 30, 1998.  At March 31, 1999
the  current  ratio  was  1.3:1.  On  November  30,  1998  the  Company  paid
approximately  $3,600,000  owed  to  Continental  Healthcare  Systems,  Inc.
("Continental")  related to the acquisition of the Pharmakon and JAC divisions
of  Continental. The balance in notes payable at the end of March 31, 1999 was
owed  to  two directors and another person. The Company is currently operating
with  existing cash balances and will review other financing needs and general
cash  requirements  on  an  on-going  basis.

YEAR 2000 COMPLIANCE - AS OF MAY 13, 1999

     IN  GENERAL  -  The  following  statements  are  a  "Year  2000 Readiness
Disclosure"  within  the  meaning  of  the Year 2000 Information and Readiness
Disclosure  Act.

     Mediware  Information  Systems,  Inc.  develops,  manufactures, sells and
provides  support  for  management  information  systems  that  are  used  by
hospitals.    The  Company  sells  software products in three distinct areas -
pharmacy,  blood  bank,  and operating room.  The Company's pharmacy and blood
bank  divisions  each  offer  multiple  products.

     The  Year  2000  issue  is  the result of computer programs being written
using  two  digits rather than four to define the applicable year.  Any of the
Company's  computer programs or products that have date sensitive software may
recognize  a date using "00" as the year 1900 rather than the year 2000.  This
could  result  in  a  system failure, loss of data, or miscalculations causing
disruption of operations.  The General Manager of each division of the company
has conducted a Year 2000 review of their operations focusing on the company's
products  and  their  use by its clients, the computers, operating systems and
data  bases  used  in conjunction with its products and the company's internal
operations.

     The  Company  is  performing  Year 2000 date-protocol tests and providing
remedial  action,  as needed, for all of its products, and is conducting tests
on  its  internal  information  technology  ("IT") systems and non-information
technology  ("Non-IT")  systems that contain embedded microchips.  The Company
is also investigating the Year 2000 preparedness of third parties with whom it
has  material relationships, such as suppliers of hardware, database software,
operating  systems, network operating systems and utility programs who provide
components on which the Company's software products are operated.  This review
includes  the  submission  of questionnaires on Year 2000 preparedness to such
third parties, whose failure to be Year 2000 compliant could negatively effect
the  operation  of  the  Company's  products  and  accordingly have a material
adverse  effect  on  the  Company.

    All of the Company's clients using older versions of its software products
have  been notified by "U.S. Mail" (of which several recent mailings were sent
"certified")  that  they  are  entitled  to  upgrade  to  Year 2000 compatible
versions  with  no  charge for the compatible version software.  However, some
clients  have  elected  not to do so for a variety of reasons.  The company is
working  with  clients who wish to upgrade to address Year 2000 issues.  These
clients  either  have been upgraded to compatible versions or are scheduled to
be upgraded to compatible versions of the company's software by the end of the
calendar  year.    The  company  is  assisting  those clients to upgrade using
electronic  access  from  the  company's  facilities and/or on-site assistance
where  appropriate and based on specific arrangements that have been made with
the  customer.    If  the  client  desires  on-site assistance, the company is
assessing  its  normal  charges.    These  services are being conducted in the
ordinary  course  of the company's business by its employees, and the costs to
the  company  are  not  expected  to  be material.  However, clients have been
notified that they are responsible for ensuring that their hardware, operating
systems,  computer BIOS, and networking software are Year 2000 compatible, and
will  be  compatible  with  the  upgraded  software  versions  provided by the
company, and must cooperate with the company in scheduling installation of the
software  upgrades.    The  failure  to  successfully meet any or all of these
conditions  could  result  in effected customers being unable to operate their
software  systems, the result of which could have a material adverse effect on
the  Company's  business,  financial  condition  and  results  of  operations.

     The incremental costs to the Company in achieving Year 2000 compatibility
cannot  be  accurately predicted and will depend upon the timely completion of
tasks  by both the Company and its customers. Total costs can be substantially
affected  by  a  number  of  factors,  including  the availability and cost of
personnel trained in this area, the ability to locate and correct all relevant
computer  codes,  and  the extent of the cooperation provided by customers and
other  relevant  parties.    However, the costs incurred to make the Company's
current  versions  compatible have occurred in the ordinary course of software
development  and  enhancement  and  are  not  expected  to  be  material.

     Suppliers of the computers, operating systems and data bases necessary to
operate the current versions of the Company's software products have indicated
to  the  Company that those products are either currently Year 2000 compatible
or  will  be  by  the  end  of  1999.  The Company has conducted tests of such
computers,  operating  systems  and data bases with the Company's products now
being  marketed  and  currently  has  no  reason to believe that the Company's
products  are  not  Year  2000  compatible  when operated with such computers,
operating  systems  and  data  bases.

     Assessment  of  Year  2000  Issues Effecting the Company's Products.  The
     -------------------------------------------------------------------
problems  of  date-protocol  compatibility  in  the  Year  2000  are  somewhat
different for each of the Company's software information system products.  The
following  is  an analysis of the Year 2000 status of products offered by each
of  the  Company's  divisions.

Pharmacy  Division
------------------

     WORx:  WORx  has been designed by the Company to meet conditions for Year
2000  readiness  from  its inception.  As a client/server application, several
layers  of  software  manipulate data.  This data is stored within an Informix
relational  database,  which supports dates beyond December 31, 1999. The WORx
client  (end-user  workstation) runs under Microsoft Windows, uses the Windows
date formats, and will support dates beyond December 31, 1999.   The Company's
Pharmacy  Division  has successfully completed the internal Alpha and external
Beta testing of its WORx software using the most current release, Version 1.3,
for  all  of  its  testing  scenarios.    WORx  has been found to be Year 2000
compatible,  and  all  customers  have  received  this  most  current release.
Certain  of  the  WORx  customers  have not yet installed version 1.3, and are
running  WORx  Version  1.1.    Although  the  company  has  not conducted Y2K
certification  testing  on  Version  1.1,  the  company  has  a high degree of
certainty  that  Version  1.1  operates in the same manner as Version 1.3 with
respect  to  processing  of  dates  beyond  December  31,  1999.



<PAGE>


    DIGIMEDICS XA INPATIENT:  The Company's Pharmacy Division has successfully
completed  the  internal  alpha  and  external Beta testing Version 3.0 of its
Digimedics XA Inpatient pharmacy system and is currently making this Year 2000
compatible  version  available  to customers wishing to upgrade their systems.

     DIGIMEDICS XA OUTPATIENT:  The  Company's Pharmacy Division is finalizing
both internal Alpha and external Beta testing Version 3.0 of its Digimedics XA
Outpatient  pharmacy  system  and  expects  to  make this Year 2000 compatible
software  available  to  its  customers  by  the  end  of  May  31,  1999.

     PHARMAKON  "MINI"  (UNIX  BASED):  The Company's  Pharmacy  Division  has
successfully completed the internal alpha and external Beta testing of version
3.5  of  its  "Unix  based"  pharmacy  system, known as Mini, and is currently
making  this  Year  2000  compatible version available to customers wishing to
upgrade  their  systems.

     PHARMAKON "MAINFRAME":  The Company's Pharmacy division has  successfully
completed  the  internal Alpha and external Beta testing of Version 5.0 of its
"Mainframe  based"  pharmacy  system,  which  was  determined  to be Year 2000
compatible.    Version  5.0  of  the Mainframe product is currently being made
available  to  those  customers  wishing  to  upgrade  their  systems.

     The  new  versions  of  Digimedics  XA,  Pharmakon  "Mini", and Pharmakon
"Mainframe"  discussed above incorporate upgrades of the Company's application
software  systems  necessary for Year 2000 compatibility.  These releases will
be  distributed  to  customers  under  the  Company's  normal software support
contract  procedures  without cost.  However, depending upon the configuration
of  their  current  information  systems, some customers may incur other costs
associated with the acquisition of new hardware, third party data bases and/or
operating  systems  that  are  needed in order for the Company's upgrade to be
installed.    Furthermore,  the  computer  and operating system platforms of a
number  of  hospitals  will  not accommodate the Year 2000 compatible software
revisions  distributed  by  the  Company, and these hospitals must acquire and
bear  the  cost  of new computer hardware and associated operating systems and
third  party  data  bases  if  they  desire  to install the Company's software
upgrades.

JAC
---

     The  Company's  United  Kingdom  subsidiary,  JAC,  sells and distributes
information  systems  for hospital pharmacies in the United Kingdom.  In early
1998,  JAC  commenced notifying its clients of the appropriate steps they must
take  to ensure their entire computer system meets all aspects of the National
Health  Service  ("NHS")  directive  for  Year  2000  compatibility.   The NHS
directive  required  each  Trust  (hospital)  to  have  either  upgraded their
operating  systems to be Year 2000 compatible, have a plan to upgrade, or have
contingency  plans ready by December 31, 1998.  Although the JAC stock control
pharmacy  system  has  been  internally and externally certified as being Year
2000  compatible,  JAC  is  aware that some of its clients may have to upgrade
certain components of their computer hardware and associated operating systems
and  pharmacy  data  bases to ensure full compatibility.  In this respect, JAC
has  commenced  notifying  all  of  its  clients  of this issue in writing, by
telephone, and through articles in its newsletter, and has raised the issue at
its  National  and  Local  User  Group  meetings.

Operating  Room  Division
-------------------------

     The  Operating  Room  Division  has successfully completed testing of the
Surgiware  product  and has determined that it is Year 2000 compatible.  A new
Year  2000 compatible revision, release 5.2, is now being offered to hospitals
as  part  of  the  normal  support  procedures  of  the Company.  However, the
computer  platforms  of a number of hospitals will not accommodate the updates
necessary to become Year 2000 ready, and these hospitals must bear the cost of
new computer hardware and associated operating systems and operating room data
bases.

Blood  Bank  Division
---------------------

     HEMOCARE:  The  Company's  Blood Bank Division has successfully completed
testing of Version 5.2.1 of its "Unix based" Hemocare blood bank system, which
was  determined  to  be  Year  2000 compatible.  Version 5.2.1 of the Hemocare
product  will  be made available to the Company's installed client base by May
31,  1999  as  part  of  the  Company's  normal  software  support procedures.

     INFORMEDICS  LIFELINE: The Company's Blood Bank Division has successfully
completed  testing of Version 4.3 of its Lifeline blood bank system, which was
determined to be Year 2000 compatible.  Version 4.3 of the Lifeline product is
currently  being made available to the Company's installed client base as part
of  the  Company's  normal  software  support  procedures

     INFORMEDICS STARPATH: The Company's Blood Bank Division has completed its
own  internal  testing  of Version 6.4C of its StarPath pathology product, and
will  finalize  external  Beta  testing  by the end of May, 99.  Assuming Beta
testing  is  successful,  this  product will be made available to all StarPath
customers starting June 1999, as part of the company's normal software support
procedures.

     The  new  versions  of  Hemocare,  Informedics  Lifeline  and Informedics
StarPath  discussed  above  incorporate  upgrades of the Company's application
software  systems  necessary for Year 2000 compatibility.  These releases will
be  distributed  to  customers  under  the  Company's  normal software support
contract  procedures  without cost.  However, depending upon the configuration
of  their  current  information  systems, some customers may incur other costs
associated with the acquisition of new hardware, third party data bases and/or
operating  systems  that  are  needed in order for the Company's upgrade to be
installed.    Furthermore,  the  computer  and operating system platforms of a
number  of  hospitals  will  not accommodate the Year 2000 compatible software
revisions  distributed  by  the  Company, and these hospitals must acquire and
bear  the  cost  of new computer hardware and associated operating systems and
pharmacy data bases if they desire to install the Company's software upgrades.

Interfaces  to  Other  Applications
-----------------------------------

     The  Company's  software  products interchange data with many third party
systems through interfaces that may be unique to the client or the third party
system.  Such interfaces or data interchanged may contain inaccuracies or such
data  may  not  be  in  a format that allows the company's system to correctly
identify  the  data.   There  can be no assurance that the company will not be
subject  to claims that result from the failure of such third party systems or
their related interfaces to be year 2000 compliant.  These claims, even if not
meritorious,  could be expensive to defend.  Although the Company believes its
Year 2000 review and the actions it has taken and plans to take in response to
the  review  are  appropriate,  there  can  be  no  assurance  that the review
identified  all  possible  issues  or  that  all  identified  issues  will  be
satisfactorily  resolved.  A material failure of the Company's internal system
to  be  Year 2000 compliant, a material failure in suppliers of the computers,
operating  systems  and  databases  used  in  conjunction  with  the company's
products  to  be  Year  2000  compliant or a material delay in client projects
related  to  Year  2000  issues  could  have  a material adverse effect on the
company's  business,  results  of  operations  or  financial  condition.

Internal  Assessment  of  Year  2000  Readiness
-----------------------------------------------

     The Company has assigned a project team to examine relationships with all
of  its  vendors,  including suppliers of both IT and Non-IT Systems regarding
Year  2000 readiness.  All vendors that supply the Company with information or
critical services, process information for the Company, or provide internal IT
or Non-IT Systems using a microprocessor will be queried as to their Year 2000
readiness  and  the Year 2000 compliance status of products they have provided
to  the  Company.

     The  Company  has  completed its initial assessment of such areas and has
found no material Year 2000 problems with respect to its IT and Non-IT Systems.
However,  the  Company  intends to make a second and final inspection of these
systems  by  the  end  of  September  1999.


<PAGE>

                                  SIGNATURES

     Pursuant  to the requirements of the Securities Exchange Act of 1934, the
Registrant  has  duly  caused  this  report  to be signed on its behalf by the
undersigned,  thereunto  duly  authorized.


                                         MEDIWARE  Information  Systems,  Inc.
                                         -------------------------------------
                                                    (Registrant)



   May 19, 1999                          By: 
---------------------                       --------------------------
     (Date)                                       John  Esposito
                                                President  and  CEO


   May 19, 1999                          By: 
---------------------                       --------------------------
     (Date)                                       Charles A. Merola
                                               Chief Financial Officer

<PAGE>


<TABLE>
<CAPTION>

                         MEDIWARE INFORMATION SYSTEMS, INC. AND SUBSIDIARIES

                                           EXHIBIT 11

                       SCHEDULE OF COMPUTATION OF NET INCOME (LOSS) PER SHARE

                                         Three months    Three months      Nine months   Nine months
                                            Ended           ended            ended          ended
                                           March 31,      March 31,         March 31,     March 31,

<S>                                    <C>            <C>              <C>              <C>
                                                   <C>           <C>                <C>          <C>
                                               1999          1998              1999         1998

Net Income (Loss)                       $     966,000  $    649,000        ($1,857,000)  $2,065,000
                                        -------------  ------------       -------------  ----------
Weighted Average Share
Outstanding                                 6,066,000     5,523,000          5,914,000    5,417,000
Effect of Dilutive
Securities: Common
Stock Equivalents
(Options & Warrants)                        1,029,000     1,185,000             --        1,148,000
                                        -------------  ------------       -------------  ----------

Average shares
     outstanding assuming
     dilution                               7,095,000     6,708,000          5,914,000    6,565,000
                                        -------------  ------------       -------------  ----------


Basic earnings per share                        $ .16         $ .12              ($.31)       $ .38
Diluted earnings per
     share                                      $ .14         $ .10              ($.31)       $ .31
                                        ---------------  ------------     -------------  ----------
</TABLE>

[ARTICLE] 5
<TABLE>
<S>                             <C>
[PERIOD-TYPE]                   9-MOS
[FISCAL-YEAR-END]                          JUN-30-1999
[PERIOD-END]                               MAR-31-1999
[CASH]                                            3658
[SECURITIES]                                         0
[RECEIVABLES]                                     9335
[ALLOWANCES]                                       472
[INVENTORY]                                        453
[CURRENT-ASSETS]                                 14236
[PP&E]                                            4250
[DEPRECIATION]                                    2431
[TOTAL-ASSETS]                                   26475
[CURRENT-LIABILITIES]                            11051
[BONDS]                                              0
[PREFERRED-MANDATORY]                                0
[PREFERRED]                                          0
[COMMON]                                           610
[OTHER-SE]                                       21164
[TOTAL-LIABILITY-AND-EQUITY]                     26475
[SALES]                                          20363
[TOTAL-REVENUES]                                 20363
[CGS]                                             5920
[TOTAL-COSTS]                                    21690
[OTHER-EXPENSES]                                     0
[LOSS-PROVISION]                                     0
[INTEREST-EXPENSE]                                 143
<LOSS-PRETAX>                                     1380
[INCOME-TAX]                                       477
<LOSS-CONTINUING>                                 1857
[DISCONTINUED]                                       0
[EXTRAORDINARY]                                      0
[CHANGES]                                            0
<NET-LOSS>                                        1857
[EPS-PRIMARY]                                      .31
[EPS-DILUTED]                                      .31
</TABLE>